New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:12 EDTHSP, MDCO, NVDA, STXS, DRTX, MRVL, RBCN, ARTX, MDR, CLNE, ISRG, UAL, VRNTOn The Fly: Pre-market Movers
HIGHER: Intuitive Surgical (ISRG), up 10% after announcing FDA clearance for new da Vinci Xi Surgical System... Clean Energy (CLNE), up 4% after beginning fueling at two stations, signing agreements... Durata Therapeutics (DRTX), up 8% after an FDA Committee voted in favor of its Dalvance injection for the treatment of certain acute bacterial skin and skin structure infections... Rubicon (RBCN), up 7.9% following upgrade at JPMorgan... United Continental (UAL), up 2.2% following upgrade at UBS... NVIDIA (NVDA), up 3% after upgrade at JMP Securities... Marvell (MRVL), up 4% after announcing it plans to appeal patent decision against it... Stereotaxis (STXS), up 12% after submitting 510 Premarket Notification with the FDA for the Vdrive Robotic system... Verint Systems (VRNT), up 5% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: Arotech (ARTX), down 11% after reporting fiscal year earnings and revenue that disappointed... The Medicines Company (MDCO), down 16% after court ruled the company failed to prove that Hospira's (HSP) generic Angiomax product infringed its patents... McDermott (MDR), down 5.8% after filing to sell 10M tangible equity units and saying that its first quarter results may differ "substantially" from the company's expectation.
News For UAL;RBCN;NVDA;ISRG;MRVL;MDCO;CLNE;DRTX;HSP;MDR;STXS;VRNT;ARTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 25, 2015
06:07 EDTMRVLMarvell downgraded to Hold from Buy at Stifel
Subscribe for More Information
05:20 EDTMDRMcDermott and Petrofac form five-year strategic alliance
McDermott and Petrofac Limited announced they have formed a strategic marketing alliance to pursue top-tier deepwater subsea, umbilical, riser and flowline, or SURF, projects. The five-year alliance expects to provide oil and gas companies a competitive, integrated solution across a broad range of complex engineer, procure, construct, install Subsea projects in deep and ultra-deepwater across the US Gulf of Mexico, Mexico, Brazil, the North Sea, Mediterranean and West Africa. SURF projects are expected to be above $200M, with the project scope anticipated to be split between partners roughly equally, but according to the specifics of a particular opportunity, and governed by separate project agreements.
February 24, 2015
10:08 EDTMRVLOptions with decreasing implied volatility
Subscribe for More Information
07:30 EDTUALJPMorgan to hold a conference
Global High Yield & Leveraged Finance Conference is being held in Miami Beach, FL on February 23-25 with webcasted company presentations to begin on February 24 at 7:40 am; not all company presentations may be webcasted. Webcast Link
06:29 EDTUALCriticism grows against U.S. airline attempts to limit Gulf airlines, WSJ says
Subscribe for More Information
February 23, 2015
16:17 EDTUALBuckeye Partners reduces FY14 revenue by $40M due to settlement discussions
Buckeye Partners (BPL) announced revisions to its financial results for Q4 and FY14 due to a recent development. As has been previously disclosed, commencing in September 2012, Delta Air Lines (DAL), JetBlue (JBLU), United/Continental Air Lines (UAL), US Airways, and American Airlines (AAL) filed complaints with the Federal Energy Regulatory Commission challenging rates for transportation of jet fuel from New Jersey to three New York City area airports charged by Buckeye Pipe Line Company, an operating subsidiary of Buckeye. The Airlines are seeking payments for alleged past excessive charges and prospective tariff rate reductions. As the litigation has progressed, BPLC and the Airlines have continued to pursue settlement discussions. Due to positive developments in those settlement discussions subsequent to Buckeye's issuance of its 2014 earnings on Friday, February 6, Buckeye has recorded a reduction in revenue in the amount of $40M for the year ended December 31, 2014 in accordance with applicable accounting guidance regarding contingencies. This reduction in revenue is a one-time charge; therefore, Adjusted EBITDA and distributable cash flow for 2014 remain as reported on February 6th. The $40M is based upon a settlement offer made by BPLC to satisfy the claims for alleged past excessive charges through December 31, 2014, which offer has not been accepted by the Airlines. "While we continue to pursue settlement of this matter, we are not able to predict with certainty the final outcome of the proceeding, should it be carried through to its conclusion, or whether we can reach a satisfactory settlement and, if so, whether or not it will be on more or less favorable terms," the company said.
February 20, 2015
17:20 EDTUALUnited Continental says cooperating with government investigation
Subscribe for More Information
10:22 EDTMRVLMarvell reiterated as a Sell at Goldman
Subscribe for More Information
10:01 EDTMRVLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:23 EDTMRVLMarvell willingness to explore alternatives a positive, says Brean Capital
Brean Capital noted Marvell reported a top-line miss but beat earnings by a penny and the firm said it was disappointed by the company's lower guidance. The firm believes that management's comment regarding their willingness to explore alternatives for its mobile business is positive and that a sale or joint venture could lead to significant upside. Brean Capital maintained its Buy rating and $17 price target on Marvell shares.
07:20 EDTMRVLMarvell says will consider 'anything that makes sense' for mobile business
Subscribe for More Information
06:02 EDTMRVLMarvell upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
February 19, 2015
18:19 EDTMRVLOn The Fly: After Hours Movers
Subscribe for More Information
16:23 EDTMRVLMarvell sees Q1 EPS 18c plus/minus 1c, consensus 22c
Subscribe for More Information
16:21 EDTMRVLMarvell reports Q4 EPS 25c, consensus 24c
Reports Q4 revenue $857M, consensus $889.88M.
15:32 EDTMRVLNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Public Storage (PSA), consensus $2.19... Intuit (INTU), consensus (13c)... Consolidated Edison (ED), consensus 55c... Nordstrom (JWN), consensus $1.35... Mohawk Industries (MHK), consensus $2.21... Newmont Mining (NEM), consensus 10c... Frontier Communications (FTR), consensus 5c... Brocade Communications (BRCD), consensus 24c... Bruker (BRKR), consensus 29c... Rovi (ROVI), consensus 41c... Marvell Technology (MRVL), consensus 24c... MRC Global (MRC), consensus 46c... Equinix (EQIX), consensus $1.03.
15:11 EDTMRVLMarvell February 16.5 straddle priced for 5.6% movement into Q4
Subscribe for More Information
09:59 EDTUALOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:57 EDTMRVLMarvell volatility elevated into Q4 and outlook
Subscribe for More Information
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use